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Abstract Circulating tumor cells (CTCs) can be identi-
fied in approximately 25 % of stage I-III breast cancer
patients; CTCs presence is a predictor of poor outcome in
metastatic breast cancer, but little is known regarding the
prognostic significance of CTCs in non-metastatic triple-
negative breast cancer (TNBC) patients. The aim of this
study was to determine whether CTCs predict worse out-
come in non-metastatic TNBC patients. We evaluated
CTCs in 113 patients with stages I-III TNBC at the time of
definitive surgery. CTCs were assessed using the Cell-
Search System. Progression-free and overall survival
were defined as time elapsed between date of diagnosis and
either date of clinical disease progression, death, or last
follow-up. Log-rank test and Cox regression analysis were
used to determine associations of CTCs with progression-
free and overall survival. The median follow-up was
40 months. CTCs were identified in 23/113 (20 %) of
patients. No primary tumor characteristic or lymph node
status predicted the presence of CTCs. The identification of
C2 CTCs predicted shorter progression-free (log rank
P B 0.001; hazard ratio 8.30, 95 % CI 2.61–26.37) and
overall survival (log rank P = 0.0004; hazard ratio 7.19,
95 % CI 1.98–26.06) versus survival for patients with \2
CTCs. Two or more CTCs predict shorter progression-free
and overall survival in TNBC patients. Larger studies are
needed to determine whether CTC assessment provides
beneficial information that could be used in stratifying
TNBC patients at increased risk for disease progression.
Finally, CTCs characterization could facilitate the devel-
opment of novel treatment approaches for TNBC.
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Introduction
Breast cancer, the most frequently diagnosed cancer and
the leading cause of cancer deaths among women, is a
heterogeneous disease that is classified and subtyped using
clinical and pathologic features including patient age and
tumor size, axillary node involvement, histologic grade,
estrogen (ER) and progesterone (PR) hormone receptor
status, and human epidermal growth factor receptor 2
(HER2) amplification. ER and/or PR receptors are
expressed in a majority of breast cancers, and HER2 is
amplified in approximately 20 % of cases [1]. Triple-neg-
ative breast cancer (TNBC) is an aggressive phenotype
comprising 10–20 % of all breast cancers [1]. Triple-neg-
ative breast tumors lack ER, PR, and HER2 expression.
Because of the absence of ER and HER2 expression and
the aggressive nature of TNBC, effective management of
TNBC patients remains a challenge in the clinic. Triple-
negative patients are typically treated sequentially with a
combination of chemotherapy, surgery, and radiation.
These tumors respond favorably to neoadjuvant chemo-
therapy (NACT), and TNBC patients are more likely to
achieve pathologic complete response (pCR) following
completion of NACT than are breast cancer patients with
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non-triple-negative tumors [2, 3]. Although pCR predicted
excellent survival regardless of tumor receptor status,
TNBC patients with residual disease following NACT
experience significantly shorter disease-free and overall
survival than patients with non-triple-negative tumors and
residual disease after NACT [4–6].
Overall, numerous published studies have shown that
TNBC patients exhibit significantly shorter overall survival
than do patients with other breast cancer subtypes, inde-
pendent of clinicopatholigic characteristics such as tumor
size/grade and lymph node status [2, 4, 6]. Interestingly,
TNBC patients typically recur within the first 3 years fol-
lowing treatment [3, 4, 6] with a propensity toward visceral
and cerebral (not bone or lymph node) metastases [7, 8].
Distant metastasis remains the primary cause of death
for breast cancer patients. Historically, most clinical
research efforts have focused on the prognostic significance
of micrometastatic spread of cancer cells to lymph nodes;
to date, lymph node positivity is the most powerful pre-
dictor of disease recurrence in patients with non-metastatic
breast cancer. However, a significant number of patients
with lymph node-negative disease recur, whereas almost a
third of patients with lymph node-positive disease do not
have a recurrence within 10 years following treatment [9,
10]. Over the past decade, improved enrichment and
detection techniques have enabled clinical researchers to
pursue studies to identify and determine the prognostic
significance of occult micrometastatic cells within the
blood [circulating tumor cells (CTCs) ]. Although the
mechanisms mediating micrometastatic dissemination to
the bloodstream are unknown, we know that these rare cells
typically remain undetected by standard pathologic
assessments and imaging technologies. CTCs are hetero-
geneous populations of cells with varying viability, dor-
mancy, biomarker expression, and metastatic capabilities.
This heterogeneity makes both detecting CTCs and deter-
mining their clinical importance a challenge. Originally,
circulating tumor cell studies focused on identification and
significance in the metastatic setting. However, since
metastatic patients represent only a small percentage of
breast cancer cases, many research groups are investigating
the prognostic significance of CTCs in the non-metastatic
setting. In theory, routine circulating tumor cell analyses
have the potential of providing ‘‘real-time’’ assessments of
occult micrometastatic dissemination and recurrence risk
throughout treatment and during routine follow-up visits.
The Cell Search System (Janssen, Raritan, NJ) can
detect as few as one CTC per 7.5 mL of peripheral blood
and to date remains the only U.S. Food and Drug
Administration-approved methodology for CTC detection
in patients with metastatic breast, colorectal, and prostate
cancers. Using this methodology, the presence of five or
more CTCs per 7.5 mL blood prior to administration of
systemic treatment has been shown to be an independent
predictor of shortened progression-free and overall survival
in metastatic breast cancer [11]. Data are emerging
regarding the predictive significance of CTCs in patients
with non-metastatic breast cancer. Results from the French
REMAGUS trial [12], the German SUCCESS-A trial [13],
and a recent report from our group [14] indicate that the
identification of one or more circulating tumor cell pre-
dicted progression-free and overall survival in patients with
non-metastatic breast cancer. However, no data have been
published about the prognostic significance of circulating
tumor cell identification specifically in patients with non-
metastatic TNBC.
We hypothesized that the presence of CTCs would
independently predict shorter progression-free and overall
survival in patients with non-metastatic TNBC, regardless of
axillary lymph node status or other primary tumor charac-
teristics such as tumor size and grade. If circulating tumor
cell presence was to add to the currently available prognostic
information, this would help identify TNBC patients who
remain at high risk for disease progression and death. To test
our hypothesis, we evaluated CTCs in patients with stages
I-III TNBC at the time of definitive surgery.
Materials and methods
Patients
This study included 113 patients with stages I-III TNBC
who underwent surgery for their primary tumor between
February 2005 and February 2012. All eligible TNBC
patients with non-metastatic breast cancer seen by Drs.
Lucci, Kuerer, and Bedrosian at The University of Texas
MD Anderson Cancer Center were given an opportunity to
enroll in this study. The institutional review board at The
University of Texas MD Anderson Cancer Center approved
this prospective study (04-0698; PI: A.L.), which included
circulating tumor cell assessment at a single time point just
prior to primary surgery for breast cancer. Patients with
bilateral breast cancer or any other malignancy within
5 years of diagnosis of the current cancer were ineligible
for this study.
We obtained informed written consent from all patients
prior to blood collection. Enrollment was strictly voluntary;
patients did not receive a stipend for participating. Indi-
vidual patient results were blinded from investigators using
a random number system as a unique patient identifier.
Staging and classification
TNM staging [primary tumor (T), regional nodes (N), dis-
tant metastases (M)] and tumor grade were designated
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according to the criteria of the American Joint Commission
on Cancer (AJCC) [15] and Black’s nuclear grading system
[16], respectively. Clinical stage was defined as the TNM
stage determined at the time of the first diagnostic procedure
confirming the invasive component of the tumor. Tumor
sections were immunostained for ER, PR, and HER2 using
previously published procedures [17]. Primary breast tumors
that expressed nuclear staining in C1 % of tumor cells were
considered positive for ER and/or PR expression. Immuno-
staining results for HER2 were scored as positive when
[10 % of the tumor cells had membranous staining or when
fluorescence in situ hybridization (FISH) for HER2 gene
amplification using the Abbott PathVysion HER2 DNA
probe kit (Abbott Laboratories, Abbott Park, Ill) yielded a
HER2/CEP17 ratio of[2.2. TNBC was defined by absence
of ER and PR expression and the absence of HER-2
immunostaining and/or gene amplification in the primary
tumor. Tumors were immunostained and considered Ki-67
positive when C35 % of tumor cells exhibited Ki-67
staining.
Isolation, staining, and enumeration of circulating
tumor cells
Peripheral blood (75 mL) was collected at the time of pri-
mary tumor surgery but prior to any surgical manipulation of
the primary tumor. Circulating tumor cell status was deter-
mined using the CellSearch System (Janssen Diagnostics,
LLC) within 72 h of blood collection. This semi-automated
technology uses antibody-coated magnetic beads to enrich
blood samples for cells expressing the epithelial-cell-adhe-
sion molecule, labels the nuclei of these enriched cells with
the fluorescent dye 4,2-diamidino-2-phenylindole dihydro-
chloride, and stains the enriched cells using a combination of
CK 8,18,19, and CD45 fluorescent antibodies. A semi-
automated fluorescence-based microscope system was
Table 1 Patient demographics and characteristics
Variables Overall cohort 1 or more circulating tumor cells P value (Chi squared test P value)
Number of subjects (%) Positive (%) Negative (%)
Total subjects 113 23 (20 %) 71 (80 %) P = 0.54
Mean age (years) 54 (range 28–80) 55 54
Median follow-up (months) 40 (range 6–88) 36 40
Tumor size P = 0.61^
\2 cm (T1) 30 (27 %) 5 (22 %) 19 (27 %)
2–5 cm (T2) 48 (42 %) 8 (35 %) 30 (49 %)
[5 cm (T3) 12 (11 %) 3 (13 %) 6 (9 %)
Skin/chest wall infiltration (T4) 23 (21 %) 7 (30 %) 15 (21 %)
Pathologic nodal status P = 0.55
Node negative 51 (45 %) 10 (34 %) 34 (48 %)
1–3 Lymph nodes 39 (35 %) 6 (26 %) 23 (32 %)
[3 lymph nodes 23 (20 %) 7 (30 %) 14 (20 %)
Histologic tumor grade P = 0.52#
Low grade (Grade 1) 4 (4 %) 3 (13 %) 1 (1 %)
Intermediate grade (Grade 2) 15 (13 %) 2 (9 %) 10 (14 %)
High grade (Grade 3) 92 (81 %) 18 (78 %) 58 (82 %)
Missing 2 (2 %) 0 (1 %) 2 (2 %)
Ki67 \ 35 % 16 (31 %) 4 (26 %) 10 (29 %) P = 0.62
Ki67 [ 35 % 36 (69 %) 7 (64 %) 25 (71 %)
Missinga 40 (50 %) 9 (47 %) 31 (51 %)
Neoadjuvant chemotherapy 58 (51 %) 13 (57 %) 35 (43 %) P = 0.55
Pre-menopausal women 30 (28 %) 6 (26 %) 17 (25 %) P = 0.92
Missing 5 (6 %) 1 (5 %) 4 (7 %)
a Ki67 not routinely performed in all breast cancer patients
# For High grade versus Low grade
^ For Tumor size [2 cm versus 2 or less
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employed to identify CTCs; nucleated cells were positive for
CK and negative for CD45, as described previously [11]. All
results were reviewed by a qualified laboratory technician
who was blinded to all patient data. Given the prognostic
significance of one or more CTCs in patients with non-
metastatic breast cancer, a cutoff of one or more CTCs was
considered positive in this study.
Statistical analyses
REMARK biomarker guidelines for reporting were used in
the present study [18]. We used Chi-square or Fisher’s
exact tests to determine associations between presence of
CTCs and primary tumor characteristics. Fisher’s exact test
was applied when one or more cells with expected value
was less than 5. Progression-free and overall survival were
defined as time elapsed between date of diagnosis and
either the date of clinical disease progression, death, or the
last follow-up. Log-rank tests were used to detect signifi-
cant differences between groups. Kaplan–Meier curves
were derived using STATA/IC 11.2 software (StataCorp,
College Station, TX) for comparison of groups defined by
different circulating tumor cell counts. The Cox propor-
tional hazards regression model was used to determine
univariate hazard ratios for progression-free and overall




A total of 113 patients with TNBC were enrolled in this
study, and their demographic data and characteristics are
reported in Table 1. The mean patient age was 54 years,
and median follow-up was 40 months. Thirty patients
(27 %) had T1 stage tumors, 53 patients (53 %) had T2/T3,
and 23 patients (21 %) had infiltration of the chest wall at
the time of presentation. Fifty-one patients (45 %) had
node-negative disease, 39 patients (35 %) had 1–3 positive
lymph nodes, and 23 patients (20 %) had more than 3
positive lymph nodes at the time of surgery. Grade 3 dis-
ease was observed in 92 patients (81 %), and 58 patients
(51 %) received NACT prior the time of blood draw for
circulating tumor cell analysis. Seventy-one patients
(63 %) had no CTCs, 23 patients (20 %) were positive for
one or more CTCs, 6 patients (5 %) were positive for two
or more CTCs, and 5 patients (4 %) had three or more
CTCs (Tables 2, 3).
Circulating tumor cells and progression-free survival
Patients with one or more circulating tumor cell showed
decreased progression-free survival than did patients with no
CTCs using log-rank test (P = 0.002) and Cox proportional
Table 2 Progression-free and overall survival in patients with CTCs
(A) Progression-free survival
Variable name Status Number Relapses (%) Relapse free survival
proportion at 48 months (%)
95 % C.I. P Values by
log-rank test
By number of circulating tumor cells
One or more circulating tumor cells ? 23 9/23 (39 %) 61 38–77 0.002
- 71 10/71 (14 %) 84 72–92
Two or more circulating tumor cells ? 6 4/6 (67 %) 33 5–68 B0.0001
- 88 15/88 (17 %) 81 70–86
Three or more circulating tumor cells ? 5 4/5 (80 %) 20 1–58 B0.0001
- 89 15/89 (17 %) 81 70–89
(B) Overall survival
Variable name Status Number Deaths (%) Overall survival
proportion at 48 months (%)
95 % C.I. P Values by
log-rank test
By number of circulating tumor cells
One or more circulating tumor cells ? 23 6/23 (26 %) 70 45–86 0.09
- 71 9/71 (13 %) 86 74–93
Two or more circulating tumor cells ? 6 3/6 (50 %) 30 1–72 0.0004
- 88 12/88 (14 %) 85 74–91
Three or more circulating tumor cells ? 5 3/5 (60 %) 30 1–72 0.0004
- 89 12/89 (13 %) 85 74–91
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hazards analysis (hazard ratio = 3.93; 95 % confidence
interval [CI], 1.55–9.94; P = 0.005). Nine (39 %) of
twenty-three patients with one or more circulating tumor cell
relapsed, compared to ten (13 %) of seventy-one patients
with no CTCs. The progression-free survival proportion was
much lower (61 %) in patients who had one or more CTCs
than in patients who had no CTCs (84 %) (Fig. 1a). As the
number of CTCs increased, so did the hazard ratios for
disease progression. Patients with two or more CTCs
showed decreased progression-free survival than did patients
with less than two CTCs using log-rank test (P B 0.0001)
and Cox proportional hazards model analysis (hazard
ratio = 8.30; 95 % CI, 2.61–26.37; P = 0.003). Four
(67 %) of six patients who had two or more CTCs relapsed
compared with fifteen (17 %) of eighty-eight patients who
had less than two CTCs. The progression-free survival was
much lower (33 %) in patients who had two or more CTCs
than in patients who had less than two CTCs (81 %)
(Fig. 1b). Patients with three or more CTCs showed
decreased progression-free survival than did patients with
less than three CTCs using log-rank test (P B 0.0001) and
Cox proportional hazards analysis (hazard ratio = 9.89;
Table 3 Cox regression univariate analyses of patient survival
according to presence of CTCs
Hazard
ratio
95 % C.I. P Value
Progression-free survival




1–3 Lymph nodes 1.62 0.55–4.8
[3 Lymph nodes 5.18 1.87–14.32
Histological high grade 0.67 0.25–1.81 0.45
Neoadjuvant chemotherapy 1.55 0.67–3.59 0.30
One or more circulating tumor
cells
3.93 1.55–9.94 0.005
Two or more circulating tumor
cells
8.30 2.61–26.37 0.003








1–3 Lymph nodes 1.72 0.52–5.64
[3 Lymph nodes 5.06 1.69–15.18
Histological high grade 0.87 0.29–2.62 0.81
Neoadjuvant chemotherapy 1.58 0.64–3.89 0.31
One or more circulating tumor
cells
2.36 0.84–6.65 0.12
Two or more circulating tumor
cells
7.19 1.98–26.06 0.01
Three or more circulating
tumor cells
7.19 1.98–26.06 0.01
Fig. 1 Probability of progression-free survival. Kaplan–Meier sur-
vival estimates of probabilities of progression-free survival according
to circulating tumor cells in operable breast cancer. a The probability
of progression-free survival in patients with CTC count C1 (Hazard
ratio 3.93; 95 % CI 1.55 –9.94; log rank P = 0.002) b probability of
progression-free survival in patients with CTC count C2 (Hazard ratio
8.30; 95 % CI 2.61–26.37; log rank P B 0.0001) c probability of
progression-free survival in patients with CTC count C3 (Hazard ratio
9.89; 95 % CI 3.14–31.13; log rank P B 0.0001)
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95 % CI, 3.14–31.13; P = 0.001). Four (80 %) of five
patients who had three or more CTCs relapsed compared
with fifteen (17 %) of eighty-nine patients who had less than
three CTCs. The progression-free survival proportion was
much lower (20 %) in the patients who had three or more
CTCs than in patients who had less than three CTCs (81 %)
(Fig. 1c).
Circulating tumor cells and overall survival
No significant difference in overall survival was observed
between patients with one or more circulating tumor cell
and patients with no CTCs using log-rank test (P = 0.09)
and Cox proportional hazards analysis (hazard
ratio = 2.36; 95 % CI, 0.84–6.65; P = 0.12). Six (26 %)
of twenty-three patients with one or more circulating tumor
cell died compared with nine (13 %) of seventy-one
patients with no CTCs. The overall survival proportion
(70 %) in the patients who had one or more circulating
tumor cell did not differ significantly from that in patients
who had no CTCs (86 %) (Fig. 2a). However, a significant
difference in overall survival proportion was observed
between the patients who had two or more CTCs and the
patients who had less than two CTCs using log-rank test
(P = 0.0004) and Cox proportional hazards analysis
(hazard ratio = 7.19; 95 % CI, 1.98–26.05; P = 0.01).
Three (50 %) of six patients who had two or more CTCs
died compared with twelve (14 %) of eighty-eight patients
who had less than two CTCs. The overall survival pro-
portion was much lower (30 %) in the patients who had
two or more CTCs than in patients who had less than two
CTCs (85 %) (Fig. 2b). Similarly, patients with three or
more CTCs had lower overall survival rates than did
patients with less than three CTCs using log-rank test
(P = 0.0004) and Cox proportional hazards analysis
(hazard ratio = 7.19; 95 % CI, 1.98–26.06; P = 0.01).
Three (60 %) of five patients who had three or more CTCs
died compared with twelve (13 %) of eighty-nine patients
who had less than three CTCs. The overall survival pro-
portion was much lower (30 %) in patients who had three
or more CTCs than in patients who had less than three
CTCs (85 %) (Fig. 2c).
Circulating tumor cells and primary tumor
characteristics
We identified no significant correlation between circulating
tumor cell presence and tumor size (P = 0.61), grade
(P = 0.52), or Ki-67 status (P = 0.62)
Circulating tumor cells and axillary lymph node status
We identified no significant correlation between circulating
tumor cell presence and pathologic axillary lymph node
status. This lack of significant association persisted after
we stratified lymph node-positive patients into those with
Fig. 2 Probability of overall survival. Kaplan–Meier survival esti-
mates of probabilities of overall survival according to circulating
tumor cells in operable breast cancer. a The probability of overall
survival in patients with CTC count C1 (Hazard ratio 2.36; 95 % CI
0.84–6.65; log rank P = 0.09) b probability of overall survival in
patients with CTC count C2 (Hazard ratio 7.19; 95 % CI 1.98–26.06;
log rank P = 0.0004) c probability of overall survival in patients with
CTC count C3 (Hazard ratio 7.19; 95 % CI 1.98–26.06; log rank
P = 0.0004)
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one to three or more than three positive lymph nodes
(P = 0.55).
Discussion
This is one of the first reports demonstrating that the
identification of two or more CTCs independently pre-
dicted both progression-free interval and overall survival in
non-metastatic triple-negative breast cancer patients. Pre-
viously published studies included a smaller number of
triple-negative patients [11, 13] or did not assess the
prognostic significance of CTCs specifically for the triple-
negative subtype [13, 19]. In agreement with Kim et al.
[20], we found that standard prognostic indicators such as
[2 cm tumor size and high tumor grade (Grade 3) did not
often predict outcome in TNBC patients. Although tumor
size and grade were not significantly associated with cir-
culating tumor cell presence, we found that the identifica-
tion of two or more CTCs demonstrated hazard ratios as
prognostically powerful as [3 lymph node metastases for
both relapse and death. These data suggest that circulating
tumor cell assessment might provide additional prognostic
information that could be useful in identifying TNBC
patients who are at increased risk for disease progression.
We used the semi-automated CellSearch platform for
circulating tumor cell identification because it has been
used in large clinical studies, it is standardized, and it is at
present the only FDA-approved methodology for circulat-
ing tumor cell assessment (in metastatic breast, colorectal,
and prostate cancer). Interestingly, one or more CTCs were
identified in 20 % of our patient cohort even though a
majority had early-stage (69 % had T1/T2 tumors) disease.
The circulating tumor cell identification rate in this study is
in agreement with the reported ranges (19–30 %) for
patients with operable breast cancer in the GeparQuattro
[21], REMAGUS 02 [12, 22], and SUCCESS-A trials [13],
in a 2012 report by Franken et al. [19] and in 2012 and
2010 reports from our group [14, 17].
To date, circulating tumor cell information has not been
used in the clinic to stage or guide management decisions
for non-metastatic breast cancer patients. However, data
are emerging about the prognostic significance of circu-
lating tumor cell identification. The REMAGUS 02 [11,
19], SUCCESS-A trial [12], and our published report [13]
demonstrated that the presence of one or more CTCs is an
independent predictor of both progression-free and overall
survival in patients with stages I-III breast cancer. In all of
these studies, neither hormone receptor expression nor
HER2 amplification status of the primary tumor predicted
the presence of CTCs. Yet, hazard ratios associated with
progression-free and overall survival in the presence of one
or more circulating tumor cell were greater than hazard
ratios observed associated with tumor size and grade, and
presence of one or more circulating tumor cell was as
prognostically powerful as lymph node metastasis. In the
present study of patients with non-metastatic triple-nega-
tive breast cancer, the presence of one or more CTCs
predicted shortened progression-free survival (mean pro-
gression-free interval, 12.3 months versus 27.7 months for
patients with no circulating tumor cells, log-rank test
P = 0.02). The effect of one or more circulating tumor cell
on overall survival did not reach significance (log-rank
P = 0.09), but the hazard ratio of 2.36 suggests a positive
association. The lack of statistical significance is likely due
to the small sample size, the low number of events, and the
40-month follow-up period used in the present study. We
are continuing patient follow-up on our current protocol
and are enrolling new TNBC patients to determine whether
one or more circulating tumor cell predicted overall
survival.
In this study, blood samples were obtained for circulating
tumor cell analysis at the time of primary surgery, just
before surgical resection. Just over half of the patients
received NACT prior to circulating tumor cell assessment.
We found no differences (P = 0.61) in circulating tumor
cell identification rates between patients who were chemo-
naive and those who received NACT prior to circulating
tumor cell analysis. These results are in agreement with
several published reports demonstrating that CTCs can be
identified in a significant number of patients following
systemic neoadjuvant and adjuvant treatments regardless of
the types of therapies employed. After neoadjuvant therapy,
CTCs have been identified in 27–60 % of patients using
polymerase chain reaction (PCR)-based methodologies [23–
27] and in 18–49 % of patients using immunocytochemical
methods [12, 13, 22, 28]. In all of these studies, the identi-
fication of CTCs after therapy predicted worse outcome. It is
not surprising that CTCs are often identified in patients
following cytotoxic therapies that targeted dividing cells, as
CTCs have been reported to be dormant [29]. In addition,
recent reports by Gazzaniga et al. have demonstrated that
CTCs express multi-drug resistance proteins (MRPs) [30,
31]. Circulating tumor cell MRP expression independently
predicted resistance to chemotherapy, and CTC MRP
expression in metastatic breast cancer patients was associ-
ated with shortened progression-free survival. Therapies
directed against biomarkers expressed in the primary tumor
might also be ineffective against CTCs. For example,
numerous recent reports indicate that HER2-positive CTCs
can be identified in a significant number of patients with
HER2 HER2-negative primary tumors [32–37]. Since ther-
apy management is usually based solely upon primary tumor
characteristics, these patients are not typically offered anti-
HER2 therapies. Given the aggressive nature of triple-neg-
ative breast cancer and the limited targeted therapy options
Breast Cancer Res Treat (2014) 147:325–333 331
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available for these patients, circulating tumor cell identifi-
cation and characterization are particularly important. Cir-
culating tumor cell profiling might expedite the development
of novel therapeutic agents that would benefit triple-negative
patients who are at high risk for disease recurrence.
In the present study, the presence of one or more cir-
culating tumor cell significantly predicted progression-free
survival for patients with TNBC regardless of the pre-
senting clinical stage of the disease. Although not statisti-
cally significant, the hazard ratio associated with one or
more circulating tumor cell was as prognostically powerful
as was [2 cm primary tumor size and the presence of 1–3
lymph node metastases. Larger clinical studies are needed
to determine the prognostic significance of one or more
circulating tumor cell in triple-negative patients. In con-
junction with ongoing research and published work, this
study provides important insight into the prognostic sig-
nificance of CTCs and establishes circulating tumor cell
identification as an important research tool for future
clinical studies investigating the development of thera-
peutic options for triple-negative patients.
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